Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762572 | 0.84 | CRHR1 (0.40) | CYP2D6CRHR1 | |
| SCHEMBL5764444 | 0.78 | NPY1R (0.52) | NPY1RCYP2D6HPGDTSHRSMN1; SMN2 | |
| SCHEMBL5763657 | 0.75 | LMNA (0.44) | HPGDSMN1; SMN2CNR1CNR2CRHR1 | |
| SCHEMBL5762383 | 0.74 | MEN1 (0.47) | SMN1; SMN2CRHR1 | |
| SCHEMBL5765581 | 0.71 | NR4A2 (0.43) | HPGDTSHRCRHR1 | |
| SCHEMBL6093643 | 0.67 | NPY1R (0.51) | NPY1RCYP2D6HPGDTSHRSMN1; SMN2 | |
| SCHEMBL5728820 | 0.67 | NPY1R (0.61) | NPY1RHPGDOPRL1CRHR1 | |
| SCHEMBL7783178 | 0.67 | NPY1R (0.44) | NPY1RCYP2D6HPGDTSHRSMN1; SMN2 | |
| SCHEMBL7791825 | 0.66 | NPY1R (0.43) | NPY1RCYP2D6HPGDTSHRSMN1; SMN2 | |
| SCHEMBL7791844 | 0.65 | NPY1R (0.43) | NPY1RCYP2D6HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074929-B2 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORP. (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1224187-B1 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORP (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-6696445-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | NPY1R 1/4885CYP2D6 2953/4885HPGD 1838/4885 |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | NPY1R 1/4885CYP2D6 3004/4885HPGD 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.